Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial.

doi:10.1038/s41392-024-01927-9

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial.

Signal transduction and targeted therapy - 13 Aug 2024

Zhou Hua-Qiang, Zhang Ya-Xiong, Chen Gang, Yu Qi-Tao, Zhang Hua, Wu Guo-Wu, Wu Di, Lin Ying-Cheng, Zhu Jun-Fei, Chen Jian-Hua, Hu Xiao-Hua, Lan Bin, Zhou Ze-Qiang, Lin Hai-Feng, Wang Zi-Bing, Lei Xiao-Lin, Pan Suo-Ming, Chen Li-Ming, Zhang Jian, Kong Tian-Dong, Yao Ji-Cheng, Zheng Xin, Li Feng, Zhang Li, Fang Wen-Feng

Abstract excerpt

Dual inhibition of vascular endothelial growth factor and epidermal growth factor receptor (EGFR) signaling pathways offers the prospect of improving the effectiveness of EFGR-targeted therapy. In this phase 3 study (ClinicalTrial.gov: NCT04028778), 315 patients with treatment-naïve, EGFR-mutated, advanced non-small cell lung cancer (NSCLC) were randomized (1:1) to receive anlotinib or placebo plus gefitinib once...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Gefitinib

Share to Indoles

Share to Protein Kinase Inhibitors

Share to Quinolines

Share to Tyrosine Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 39134529
DOI: 10.1038/s41392-024-01927-9
PMCID: PMC11319491

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial.PMID 39134529Read ↗

Efficacy and Safety of Anlotinib in EGFR-Positive Patients with Advanced Lung Adenocarcinoma Compared with Chemotherapy: A Retrospective Study.Semantic proximity Read ↗

Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.Semantic proximity Read ↗

Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.Semantic proximity Read ↗

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.Semantic proximity Read ↗

First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation.Semantic proximity Read ↗

First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial.Semantic proximity Read ↗

Efficacy and safety of anlotinib plus EGFR-TKI for advanced non-small cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials.Semantic proximity Read ↗

Erlotinib plus bevacizumab is effective in EGFR-mutant NSCLC.Semantic proximity Read ↗

First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trials.Semantic proximity Read ↗

Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC.Semantic proximity Read ↗

The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer.Semantic proximity Read ↗

Efficacy and toxicity of combined inhibition of EGFR and VEGF in patients with advanced non-small-cell lung cancer harboring activating EGFR mutations: A systematic review and meta-analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.